Voyager Therapeutics
VYGR
108 hedge funds and large institutions have $509M invested in Voyager Therapeutics in 2018 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 36 increasing their positions, 30 reducing their positions, and 13 closing their positions.
85% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 13
22% more capital invested
Capital invested by funds: $418M → $509M (+$90.4M)
20% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 30
10% more funds holding
Funds holding: 98 → 108 (+10)
3.95% more ownership
Funds ownership: 80.08% → 84.03% (+3.9%)
48% less call options, than puts
Call options by funds: $722K | Put options by funds: $1.39M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$12.2M |
| 2 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$9.79M |
| 3 |
Millennium Management
New York
|
+$7.39M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$6.6M |
| 5 |
Morgan Stanley
New York
|
+$6.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.93M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.89M |
| 3 |
TCP
Tourbillon Capital Partners
New York
|
-$3.82M |
| 4 |
LCM
Laurion Capital Management
New York
|
-$3.76M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$3.29M |
VYGR Hedge Fund Activity: Q1 2018 in Review
108 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q1 2018, worth a combined $509M — up 22% from $418M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new VYGR positions and 13 closed out — a net gain of 11 holders — while 36 added to existing stakes and 30 trimmed.
The largest buyer was State Street, adding an estimated $12.2M. The largest seller was Fidelity Investments, cutting an estimated $8.93M.
- 108 institutional investors held Voyager Therapeutics (VYGR) as of Q1 2018, up from 98 in Q4 2017.
- Funds reported $509M of Voyager Therapeutics stock for Q1 2018, up 22% quarter-over-quarter.
- 24 funds opened new Voyager Therapeutics positions in Q1 2018 and 13 closed out, a net change of +11 holders.
- The largest Voyager Therapeutics buyer in Q1 2018 was State Street, an estimated $12.2M added.
- The largest Voyager Therapeutics seller in Q1 2018 was Fidelity Investments, an estimated $8.93M sold.
Based on aggregated 13F filings for Q1 2018.